

Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028

<https://marketpublishers.com/r/A658A621B345EN.html>

Date: August 2024

Pages: 195

Price: US\$ 2,400.00 (Single User License)

ID: A658A621B345EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028 Report
Highlights:

Anti TIGIT Antibodies In Clinical Trials: > 50 Antibodies

First Anti TIGIT Antibody To Get Approval Within Next 5 Years

Global Anti TIGIT Antibodies Clinical Pipeline Insight By Company, Indication and Phase

Insight On More Than 50 Anti TIGIT Antibodies In Clinical Trials

Anti TIGIT Antibodies Market Trends by Indication & Country

Global Anti TIGIT Antibodies Market Dynamics

Anti TIGIT antibodies have emerged a promising approach in cancer immunotherapy, offering new hope for patients with various types of cancers, particularly solid cancers. TIGIT (T cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor expressed on T cells and natural killer (NK) cells, playing a crucial role in modulating immune responses. By targeting TIGIT, researchers aim to enhance the immune system's ability to recognize and eliminate cancer cells, potentially revolutionizing cancer treatment strategies.

The therapeutic potential of TIGIT as a target for cancer immunotherapy lies in its function as an immune checkpoint molecule. When TIGIT interacts with its ligands, such as CD155 and CD112, it suppresses T cell and NK cell activation, potentially allowing cancer cells to evade immune surveillance. By blocking this interaction with anti-TIGIT therapeutic approaches, researchers hope to reinvigorate the immune response against tumors, leading to improved clinical outcome for cancer patients. Among the various approaches for targeting TIGIT, monoclonal antibodies have emerged as the most widely used and promising agents. These antibodies are designed to specifically bind to TIGIT, preventing its interaction with its ligands and thus releasing the “breaks” on the immune system. Their high specificity and relatively low toxicity of antibodies make them attractive candidates for clinical development.

The field of anti-TIGIT antibody development has seen rapid progress, with over 50 candidates currently in clinical development. This robust pipeline underscores the significant interest and potential of this approach in cancer treatment. Among these, more than five anti TIGIT antibodies have advanced to phase 3 clinical trials, representing the most advanced stage of clinical development before potential regulatory approval. These include Vibostolimab, Tiragolumab and Ociperlimab, developed by the pharmaceutical market leaders, Merck Genentech and BeiGene, respectively.

These phase 3 clinical trials are assessing the safety and efficacy of these anti-TIGIT antibodies in various cancer types, with a particular focus on non-small cell lung cancer (NSCLC). The emphasis on NSCLC is not surprising, given its high prevalence and the need for more effective treatment options. NSCLC represents a significant portion of lung cancer cases and has shown promising responses to immunotherapy approaches in the past.

Several key factors are driving the market potential of anti-TIGIT antibodies. Firstly, there remains a substantial unmet medical need in cancer treatment, especially for patients who do not respond to or develop resistance to existing immunotherapies. Anti-TIGIT antibodies offer a novel mechanism of action that could address these challenges. Moreover, these antibodies show promising results in combination with established therapies like PD-1/L1 inhibitors, potentially expanding the market for both drug classes and improving treatment outcomes. This becomes visible in Merck's vision of developing a coformulation of its anti-TIGIT antibody Vibostolimab with its blockbuster anti-PD-1 antibody pembrolizumab for the treatment of various solid tumors. The broad applicability of anti-TIGIT antibodies across various cancer forms presents another significant market opportunity. While a majority of clinical trials currently focus on NSCLC, many other ongoing clinical trials are exploring their efficacy in other solid cancers tumors and hematological malignancies, which could lead to multiple approved indications, consequently increasing the anti-TIGIT antibody market size.

As evident from the examples above, the competitive landscape for the anti-TIGIT antibody market is dynamic, with major pharmaceutical companies and biotechnology firms vying for market share. While Vibostolimab leverages the company's strong position in the immuno-oncology market, another, Domvanalimab, being developed by Gilead Sciences and Arcus Biosciences, benefits from a partnership between a major pharmaceutical company and a competent biopharmaceutical company.

In conclusion, anti-TIGIT antibodies not only represent a significant advancement in cancer immunotherapy, but also present many opportunities for drug development and market expansion. With its potential to address unmet medical needs, broad applicability and alignment with personalized medicine, this emerging class of drugs is poised to capture a substantial portion of cancer immunotherapy market.

Contents

1. INTRODUCTION TO ANTI TIGIT ANTIBODY

- 1.1 Overview
- 1.2 Mechanism of Anti TIGIT Antibodies
- 1.3 Clinical Approaches to Target TIGIT

2. GLOBAL ANTI TIGIT ANTIBODIES CLINICAL TRIALS OVERVIEW

- 2.1 By Company
- 2.2 By Country
- 2.3 By Indication
- 2.4 By Patient Segment
- 2.5 By Phase

3. GLOBAL ANTI TIGIT ANTIBODIES CLINICAL PIPELINE BY COMPANY, INDICATION AND PHASE

- 3.1 Research
- 3.2 Preclinical
- 3.3 Phase I
- 3.4 Phase I/II
- 3.5 Phase II
- 3.6 Phase III

4. GLOBAL ANTI TIGIT ANTIBODIES MARKET OUTLOOK

- 4.1 Current Clinical & Market Trends
- 4.2 Future Market Outlook

5. ANTI TIGIT ANTIBODIES MARKET TRENDS BY INDICATION

- 5.1 Cancer
- 5.2 Autoimmune & Inflammatory Disorders
- 5.3 Microbial Infections

6. ANTI TIGIT ANTIBODIES MARKET BY COUNTRY

6.1 US

6.2 China

6.3 South Korea

6.4 Australia

6.5 UK

7. COMBINATIONS APPROACHES FOR TIGIT THERAPY

8. TIGIT CO INHIBITION WITH PD1 OR PDL1

9. GLOBAL ANTI TIGIT ANTIBODIES MARKET DYNAMICS

9.1 Market Drivers

9.2 Commercialization Challenges

10. COMPETITIVE LANDSCAPE

10.1 Akeso Biopharma

10.2 BeiGene

10.3 Bio-Thera Solutions

10.4 Biotheus

10.5 Compugen

10.6 FutureGen Biopharmaceutical

10.7 Merck Sharp & Dohme

10.8 Nanjing Sanhome Pharmaceutical

10.9 OriCell Therapeutics

10.10 Phio Pharmaceuticals

10.11 Roche

10.12 Shanghai Henlius Biotech

10.13 Shanghai Junshi Biosciences

10.14 Simcere Pharmaceutical Group

10.15 Tasrif Pharmaceutical

Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway

Figure 1-2: TIGIT Inhibitor – Proposed Mechanism of Action

Figure 1*3: TIGIT Inhibitor – Mechanism of Action

Figure 1-4: Binding Efficacy of Monoclonal Antibody

Figure 1-5: Binding Efficacy of Bispecific Antibodies

Figure 1-6: Advantages of Small Molecule Drugs over Therapeutic Antibodies

Figure 2-1: Global - Anti TIGIT Antibodies Clinical Trials by Company (Number of

Drugs), 2024 -2028

Figure 2-2: Global - Anti TIGIT Antibodies Clinical Trials by Country (Number of Drugs), 2024 - 2028

Figure 2-3: Global - Anti TIGIT Antibodies Clinical Trials by Indication (Number of Drugs), 2024 - 2028

Figure 2-4: Global - Anti TIGIT Antibodies Clinical Trials by Patient Segment (Number of Drugs), 2024 - 2028

Figure 2-5: Global - Anti TIGIT Antibodies Clinical Trials by Phase (Number of Drugs), 2024 -2028

Figure 4 1: Global TIGIT Therapy Fundamental Companies

Figure 4 2: Future TIGIT Market

Figure 5-1: Anti-LAG-3 (BMS-986016) & Anti-TIGIT (BMS-986207) Phase I/II (NCT04150965) Study – Initiation & Completion Year

Figure 5-2: Compugen TIGIT Antibody Cancer Pipeline

Figure 5-3: Keio University School of Medicine Research Study

Figure 5-4: University of Zurich Investigation for TIGIT Antibody to Cure Viral Infection

Figure 5-5: Combination TIGIT Therapy for Viral Infections

Figure 6-1: PD-1 Inhibitor Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) Phase II (NCT05130177) Study – Initiation & Completion Year

Figure 6-2: iTeos Therapeutics & GSK Triumph Enrolment Milestone

Figure 6-3: Bristol Myers Squibb & Agenus Preclinical Candidates, BMS-986442

Figure 6-4: Clinical TIGIT Therapy Pipeline in China

Figure 6-5: JS006 Monotherapy and in Combination With Toripalimab Phase I (NCT05061628) Study – Initiation & Completion Year

Figure 6-6: Chinese Companies TIGIT Candidates Insights

Figure 6-7: Zimberelimab with Domvanalimab Phase II (NCT04262856) Study – Initiation & Completion Year

Figure 6-8: Aspects Influencing South Korea TIGIT Market

Figure 6-9: HLX301 Phase I/II (NCT05102214) Study – Initiation & Completion Year

Figure 6-10: AZD8205 Monotherapy or in Combination with Anticancer Drugs Phase I/II (NCT05123482) Study – Initiation & Completion Year

Figure 6-11: Key Players in UK TIGIT Market

Figure 7-1: TIGIT Therapy Combinations

Figure 9-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 9-2: TIGIT Inhibitor Market Drivers

Figure 9-3: Stages of Drug Development

Table 1-1: Anti-TIGIT Monoclonal Antibodies in Development

Table 5-1: Ongoing Cancers Clinical Trials for TIGIT Therapy

Table 6-1: Ongoing US Clinical Trials for TIGIT Therapy

Table 6-2: Ongoing China Clinical Trials for TIGIT Therapy

Table 7-1: Ongoing Preclinical & Clinical Trials for Combination of TIGIT inhibitors

I would like to order

Product name: Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028

Product link: <https://marketpublishers.com/r/A658A621B345EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A658A621B345EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970